Biotech | September 21, 2021
HUTCHMED initiates a Japan bridging study to Support Surufatinib
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
MeMed BV is a first-of-its-kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes
Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%
The investment programme is expected to significantly reduce commercialisation lead times, costs and introduce more sustainable manufacturing processes
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
Telemedicine services like SAATH and E-Sanjeevani add a meta-layer to the primary health sector, thus helping upgrade the entire health care system of India
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
The event will include an exhibition and sector-wise sessions for two days with participation by officials from the Ministry of Commerce, export promotion councils and members of the industry
The medicine helps restore the balance of certain natural substances (serotonin) in the brain
Subscribe To Our Newsletter & Stay Updated
